Phase 3 TRANSCEND Study Will Evaluate Use of Felzartamab for AMR

#nephrology #kidneytransplantation Biogen recently announced the initiation of TRANSCEND (NCT06685757), a phase 3 study of felzartamab for the treatment of late antibody-mediated rejection (AMR) after kidney transplant. Antibody-mediated rejection affects approximately 23,000 US patients and is a leading cause of kidney transplant loss. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. Nephrology Times spoke with Suphamai Bunnapradist, MD, MS, professor of clinical medicine at the David Geffen School of Medicine and research director of the Connie Frank Kidney Transplant Center at UCLA, who is the principal investigator of the study.